On Friday, in the course of current trade, Shares of Pfizer Inc. (NYSE:PFE), gained 0.15%, and is now trading at $34.49.
Pfizer, declared initial results of its global survey of more than 3,600 adults with rheumatoid arthritis (RA) in 13 countries. The RA NarRAtive patient survey is the first of its kind to simultaneously evaluate the patient and healthcare professional (HCP) relationship and communication, in addition to the patient’s experience and satisfaction with treatment and disease administration. The data show that a patient’s perception of their RA and its treatment, in addition to their relationship with their HCP, can impact the administration of their disease.
The survey, created and sponsored by Pfizer, was fielded online by Harris Poll between September 2014 and January 2015 as part of the company’s ongoing global partnership with the RA NarRAtive Advisory Panel comprised of 27 RA experts – counting physicians and leaders from patient advocacy groups.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
In an opening trade, Shares of Biocept, Inc. (NASDAQ:BIOC), dipped -3.47%, and is now trading at $3.06.
Biocept, continues to build evidence of the clinical utility of its liquid biopsy offerings with an abstract at the 2015 Annual American Society of Clinical Oncology Meeting in Chicago starting on May 29, 2015.
Biocept offers a sensitive and quantitative blood-based method for the detection and monitoring of clinically actionable cancer biomarkers in order to assist doctors make treatment decisions based on genomic information gained from the tumor material. The Company is engaged in multiple clinical studies designed to demonstrate the utility of its liquid biopsy diagnostic to detect a patient’s biomarker status and for the assessment of treatment response over time.
The abstract demonstrates the clinical utility of a liquid biopsy using Biocept’s technology, not only for a patient where there is insufficient tissue from a biopsy, but also in order to better represent a patient’s biomarker status by avoiding challenges associated with tissue heterogeneity, all accomplished with a simple blood draw.
Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors.
Shares of Johnson & Johnson (NYSE:JNJ), during its Friday’s current trading session gained 0.08%, and is now trading at $101.23.
Johnson & Johnson, declared the acceptance of the March 1, 2015 binding offer from Cardinal Health to acquire its Cordis business for an approximate value of $2 billion. The offer was accepted after consultations with relevant works councils and trade unions. The company anticipates the transaction to close towards the end of 2015, subject to regulatory clearances and other customary closing conditions.
Johnson & Johnson remains dedicated to combating cardiovascular disease through its electrophysiology business, Biosense Webster, in the Medical Devices segment and its leading cardiovascular medicine, XARELTO®, in the Pharmaceutical segment.
Johnson & Johnson, together with its auxiliaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.
Finally, Prima Biomed Ltd. (NASDAQ:PBMD), gained 0.40% Friday.
Editors and readers are advised to disregard the duplicate news release with the headline, “CVac Shows Clear Trend for Overall Survival Benefit in Second Remission Ovarian Cancer in Phase II Study,” that was distributed on May 26, 2015 and sourced to Prima BioMed. The release was formerly declared on May 19, 2015 and was re-issued in error instead of this intended declaration, through the fault of PCG Advisory Group.
On May 25, 2015, Prima declared on the ASX that it has reached a contract with the US-based Database Integrations Inc. (DBI) for the two companies to commercialize iCAN, the software platform that powers Prima’s CVac cellular therapy, for use in other cellular therapies worldwide.
iCAN, which was designed by DBI to Prima’s specifications and commissioned in 2011, handles, in a scalable architecture and with a high level of automation, all the electronic records and electronic signatures associated with labelling, manufacturing operations, distribution, logistics, communications and scheduling for immuno-cellular therapies like CVac. With iCAN having significantly contributed to making CVac an efficient and relatively low cost cellular therapy in the years since 2011, Prima and DBI believe that other developers of cellular therapies will benefit from iCAN with their products. Under the Agreement being declared recently the two companies will work together to seek sub-licensees for that system. It is envisaged that Prima will earn a percentage of the revenues that Database Integrations earns from new sub-licensees.
Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product presently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
